• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在缩短或部分评估中纵向项目反应理论模型的性能。

Performance of longitudinal item response theory models in shortened or partial assessments.

机构信息

Department of Pharmaceutical Biosciences, Uppsala University, P.O. Box 591, 751 24, Uppsala, Sweden.

Merck & Co. Inc, Kenilworth, NJ, USA.

出版信息

J Pharmacokinet Pharmacodyn. 2020 Oct;47(5):461-471. doi: 10.1007/s10928-020-09697-x. Epub 2020 Jul 2.

DOI:10.1007/s10928-020-09697-x
PMID:32617833
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7520414/
Abstract

This work evaluates the performance of longitudinal item response (IR) theory models in shortened assessments using an existing model for part II and III of the MDS-UPDRS score. Based on the item information content, the assessment was reduced by removal of items in multiple increments and the models' ability to recover the item characteristics of the remaining items at each level was evaluated. This evaluation was done for both simulated and real data. The metric of comparison in both cases was the item information function. For real data, the impact of shortening on the estimated disease progression and drug effect was also studied. In the simulated data setting, the item characteristics did not differ between the full and the shortened assessments down to the lowest level of information remaining; indicating a considerable independence between items. In contrast when reducing the assessment in a real data setting, a substantial change in item information was observed for some of the items. Disease progression and drug effect estimates also decreased in the reduced assessments. These changes indicate a shift in the measured construct of the shortened assessment and warrant caution when comparing results from a partial assessment with results from the full assessment.

摘要

本研究采用 MDS-UPDRS 评分的第二部分和第三部分现有的模型,评估了在缩短评估中使用纵向项目反应(IR)理论模型的性能。根据项目的信息含量,通过逐步删除项目来减少评估,并评估模型在每个水平上恢复剩余项目特征的能力。这两种情况都使用项目信息函数进行比较。对于真实数据,还研究了缩短对估计疾病进展和药物效果的影响。在模拟数据设置中,直到最低信息水平,完整和缩短评估之间的项目特征没有差异;这表明项目之间具有相当大的独立性。相比之下,在实际数据设置中减少评估时,一些项目的项目信息发生了实质性变化。减少评估的疾病进展和药物效果估计也降低了。这些变化表明缩短评估的测量结构发生了转变,因此在将部分评估的结果与完整评估的结果进行比较时应谨慎。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/748d/7520414/0b3023e66a06/10928_2020_9697_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/748d/7520414/0daab4c572f6/10928_2020_9697_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/748d/7520414/01e82a917717/10928_2020_9697_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/748d/7520414/ccf0e9324a80/10928_2020_9697_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/748d/7520414/b3d4eefe59f6/10928_2020_9697_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/748d/7520414/0b3023e66a06/10928_2020_9697_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/748d/7520414/0daab4c572f6/10928_2020_9697_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/748d/7520414/01e82a917717/10928_2020_9697_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/748d/7520414/ccf0e9324a80/10928_2020_9697_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/748d/7520414/b3d4eefe59f6/10928_2020_9697_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/748d/7520414/0b3023e66a06/10928_2020_9697_Fig5_HTML.jpg

相似文献

1
Performance of longitudinal item response theory models in shortened or partial assessments.在缩短或部分评估中纵向项目反应理论模型的性能。
J Pharmacokinet Pharmacodyn. 2020 Oct;47(5):461-471. doi: 10.1007/s10928-020-09697-x. Epub 2020 Jul 2.
2
Item Response Theory as an Efficient Tool to Describe a Heterogeneous Clinical Rating Scale in De Novo Idiopathic Parkinson's Disease Patients.项目反应理论作为一种有效的工具,可用于描述初发性特发性帕金森病患者中具有异质性的临床评分量表。
Pharm Res. 2017 Oct;34(10):2109-2118. doi: 10.1007/s11095-017-2216-1. Epub 2017 Jul 10.
3
Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.左旋多巴对晚期帕金森病的疗效和运动功能的影响。
J Parkinsons Dis. 2018;8(1):59-70. doi: 10.3233/JPD-171181.
4
Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.MDS-UPDRS 是否能精确评估早期帕金森病的进展?帕金森病进展标志物倡议队列的研究结果。
J Neurol. 2019 Aug;266(8):1927-1936. doi: 10.1007/s00415-019-09348-3. Epub 2019 May 9.
5
Differential progression of motor impairment in levodopa-treated Parkinson's disease.左旋多巴治疗帕金森病中运动障碍的差异进展
Mov Disord. 2000 May;15(3):479-84. doi: 10.1002/1531-8257(200005)15:3<479::AID-MDS1009>3.0.CO;2-P.
6
Modeling a Composite Score in Parkinson's Disease Using Item Response Theory.使用项目反应理论对帕金森病综合评分进行建模。
AAPS J. 2017 May;19(3):837-845. doi: 10.1208/s12248-017-0058-8. Epub 2017 Feb 28.
7
The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.帕金森病症状起始侧与 MDS-UPDRS 量表第四部分(运动并发症)表现之间的关联。
J Neurol Sci. 2019 Jan 15;396:262-265. doi: 10.1016/j.jns.2018.12.002. Epub 2018 Dec 4.
8
GSK's Requip slow the loss of dopamine function in Parkinson's disease.葛兰素史克公司的罗匹尼罗可减缓帕金森病中多巴胺功能的丧失。
Aviat Space Environ Med. 2002 Jul;73(7):733.
9
Relationship between the non-motor items of the MDS-UPDRS and Quality of Life in patients with Parkinson's disease.帕金森病患者中MDS-UPDRS非运动项目与生活质量的关系
J Neurol Sci. 2015;353(1-2):87-91. doi: 10.1016/j.jns.2015.04.013. Epub 2015 Apr 17.
10
Correlation between the Movement Disorders Society Unified Parkinson's Disease rating scale (MDS-UPDRS) and the Unified Parkinson's Disease rating scale (UPDRS) during L-dopa acute challenge.左旋多巴急性冲击试验中运动障碍学会统一帕金森病评定量表(MDS-UPDRS)与帕金森病评定量表(UPDRS)的相关性。
Parkinsonism Relat Disord. 2011 Nov;17(9):705-7. doi: 10.1016/j.parkreldis.2011.07.002. Epub 2011 Jul 23.

引用本文的文献

1
Item Response Modeling and Artificial Neural Network for Differentiation of Parkinson's Patients and Subjects Without Evidence of Dopaminergic Deficit.用于区分帕金森病患者与无多巴胺能缺陷证据受试者的项目反应模型和人工神经网络
CPT Pharmacometrics Syst Pharmacol. 2025 May;14(5):881-890. doi: 10.1002/psp4.70000. Epub 2025 Mar 5.
2
Increasing Sensitivity in Patient-Reported MDS-UPDRS Items for Predicting Medication Initiation in Early PD.提高患者报告的MDS-UPDRS项目对早期帕金森病药物起始预测的敏感性。
Mov Disord Clin Pract. 2025 Feb;12(2):148-156. doi: 10.1002/mdc3.14229. Epub 2024 Oct 18.
3
Sparse item testing of clinical scales in neurology trials to alleviate burden to patients.

本文引用的文献

1
Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs.开发富亮氨酸重复激酶 2 在帕金森病中的疾病进展模型,以指导临床试验设计。
Clin Pharmacol Ther. 2020 Mar;107(3):553-562. doi: 10.1002/cpt.1634. Epub 2019 Dec 5.
2
Modeling Composite Assessment Data Using Item Response Theory.使用项目反应理论对复合评估数据进行建模。
CPT Pharmacometrics Syst Pharmacol. 2018 Apr;7(4):205-218. doi: 10.1002/psp4.12280. Epub 2018 Mar 1.
3
Motor subtype changes in early Parkinson's disease.
神经病学试验中临床量表的稀疏项目测试以减轻患者负担。
J Neurol. 2024 Oct;271(10):6847-6855. doi: 10.1007/s00415-024-12650-4. Epub 2024 Aug 30.
4
Item performance of the scale for the assessment and rating of ataxia in rare and ultra-rare genetic ataxias.罕见和超罕见遗传性共济失调评估和分级评定量表的项目表现。
CPT Pharmacometrics Syst Pharmacol. 2024 Aug;13(8):1327-1340. doi: 10.1002/psp4.13162. Epub 2024 May 21.
5
Comparison of Two Methods for Determining Item Characteristic Functions and Latent Variable Time-Course for Pharmacometric Item Response Models.两种方法测定药代动力学项目反应模型项目特征函数和潜在变量时间进程的比较。
AAPS J. 2024 Jan 25;26(1):21. doi: 10.1208/s12248-023-00883-6.
6
Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migraine.评价依瑞奈玛特对慢性和发作性偏头痛患者偏头痛特异性问卷的影响。
CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):1988-2000. doi: 10.1002/psp4.13048. Epub 2023 Oct 11.
7
Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings.同时使用运动障碍学会统一帕金森病评定量表第 2 部分和第 3 部分:将患者声音与临床医生评分相结合。
Mov Disord. 2023 Mar;38(3):453-463. doi: 10.1002/mds.29308. Epub 2023 Jan 9.
8
Application of longitudinal item response theory models to modeling Parkinson's disease progression.纵向项目反应理论模型在帕金森病进展建模中的应用。
CPT Pharmacometrics Syst Pharmacol. 2022 Oct;11(10):1382-1392. doi: 10.1002/psp4.12853. Epub 2022 Aug 9.
9
Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling.剖析帕金森病的领域:来自纵向项目反应理论建模的见解。
Mov Disord. 2022 Sep;37(9):1904-1914. doi: 10.1002/mds.29154. Epub 2022 Jul 16.
10
Novel Approach to Movement Disorder Society-Unified Parkinson's Disease Rating Scale Monitoring in Clinical Trials: Longitudinal Item Response Theory Models.临床试验中运动障碍学会统一帕金森病评定量表监测的新方法:纵向项目反应理论模型
Mov Disord Clin Pract. 2021 Aug 3;8(7):1083-1091. doi: 10.1002/mdc3.13311. eCollection 2021 Oct.
早期帕金森病的运动亚型变化。
Parkinsonism Relat Disord. 2017 Oct;43:67-72. doi: 10.1016/j.parkreldis.2017.07.018. Epub 2017 Jul 21.
4
Item Response Theory as an Efficient Tool to Describe a Heterogeneous Clinical Rating Scale in De Novo Idiopathic Parkinson's Disease Patients.项目反应理论作为一种有效的工具,可用于描述初发性特发性帕金森病患者中具有异质性的临床评分量表。
Pharm Res. 2017 Oct;34(10):2109-2118. doi: 10.1007/s11095-017-2216-1. Epub 2017 Jul 10.
5
Modeling a Composite Score in Parkinson's Disease Using Item Response Theory.使用项目反应理论对帕金森病综合评分进行建模。
AAPS J. 2017 May;19(3):837-845. doi: 10.1208/s12248-017-0058-8. Epub 2017 Feb 28.
6
Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis.项目反应理论在多发性硬化扩展残疾状态量表建模中的应用。
AAPS J. 2017 Jan;19(1):172-179. doi: 10.1208/s12248-016-9977-z. Epub 2016 Sep 15.
7
Item response theory for measurement validity.用于测量效度的项目反应理论。
Shanghai Arch Psychiatry. 2014 Jun;26(3):171-7. doi: 10.3969/j.issn.1002-0829.2014.03.010.
8
Improved utilization of ADAS-cog assessment data through item response theory based pharmacometric modeling.通过基于项目反应理论的药动学建模提高阿尔茨海默病协作组认知评估(ADAS-cog)数据的利用率。
Pharm Res. 2014 Aug;31(8):2152-65. doi: 10.1007/s11095-014-1315-5. Epub 2014 Mar 5.
9
Models for disease progression: new approaches and uses.疾病进展模型:新方法和用途。
Clin Pharmacol Ther. 2012 Jul;92(1):125-31. doi: 10.1038/clpt.2012.53. Epub 2012 May 23.
10
Use of non-parametric item response theory to develop a shortened version of the Positive and Negative Syndrome Scale (PANSS).运用非参数项目反应理论开发简明版阳性与阴性症状量表(PANSS)。
BMC Psychiatry. 2011 Nov 16;11:178. doi: 10.1186/1471-244X-11-178.